Drug Trial Radar · NCT00534677
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
Last checked: Nov 20, 2026Latest source record: Dec 5, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
320
Actual
Start
May 2004
Primary completion
Not stated
Study completion Jul 2005
Sponsor
- Lead sponsor
- Aga Khan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 26, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Terlipressin and Octreotide are two common agents used as adjuvants in the management of variceal bleeding. Both agents have been claimed equivalent to endoscopic therapy in randomized studies. There are no head to head clinical trials of these two agents available in the literature. We aimed to compare the efficacy and safety of Terlipressin and Octreotide in combination with Endoscopic Variceal band Ligation (EVL)in patients presenting with Esophageal Variceal Bleed (EVB).
Conditions
- Portal Hypertension
- Cirrhosis
- Hematemesis
- Melena
Interventions
TerlipressinDrug
2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
OctreotideDrug
Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety & EfficacyTime frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Aga Khan University Hospital
Karachi, Sindh, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.